Anti-CD30 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Drug Profile

Anti-CD30 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Alternative Names: Anti-CD30 CART cell therapy - Cellular Biomedicine Group; Anti-CD30 CART cells; CART30; CD30 specific CART cells

Latest Information Update: 30 May 2015

Price : $50

At a glance

  • Originator Chinese PLA General Hospital
  • Class Cancer vaccines; CAR-T cell therapies; Gene therapies; T lymphocyte cell therapies; Vaccines
  • Mechanism of Action CD30 antigen modulators; Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 22 May 2015 Efficacy and adverse events data from a phase I/II trial in Non-Hodgkin's lymphoma released by Cellular Biomedicine Group
  • 01 Oct 2014 Phase-I/II clinical trials in Hodgkin's disease (In adults, In the elderly, Recurrent, Treatment-resistant) in China (IV) (NCT02259556)
  • 01 Oct 2014 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (In adults, In the elderly, Recurrent, Treatment-resistant) in China (IV) (NCT02259556)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top